A Phase 2 interventional study of lenvatinib and everolimus in Renal Cell Carcinoma, sponsored by Eisai Inc.. Completed at 93 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-01.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing lenvatinib in Carcinoma, Renal Cell — 13 open to participants now, 17 under way, 2 of them phase 3. lenvatinib · Carcinoma, Renal Cell.
Among the 30 studies testing lenvatinib in Carcinoma, Renal Cell, this one is the 3rd largest by enrollment, is the only one that started in 2017, is one of 22 in phase 2, and was the 4th registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →13 of the 30 studies testing lenvatinib in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:
Jinling Hospital, China · Sites in China
Ages 18–80
Sun Yat-sen University · Sites in China
Ages 18–80
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+ · Healthy volunteers
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lenvatinib is the treatment under test here. Read study by study →
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 23 · Phase 3 2 · Phase 4 1
First in 2010; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 343 is above the median of 43 across 1,565 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 30 across the 30 interventional studies. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 6 studies filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
4 of the studies testing lenvatinib in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05319015University of Texas Southwestern Medical CenterNeoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus | 2026-12 |
| NCT07909265Cancer Institute and Hospital, Chinese Academy of Medical SciencesProspective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma | 2027-07-01 |
| NCT05012371M.D. Anderson Cancer CenterLenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer | 2027-10-25 |
| NCT07256223Fudan UniversityA Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread | 2027-11-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies testing lenvatinib in Carcinoma, Renal Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study E7080-G000-218 is a Randomized, open-label (formerly Double-blind), Phase 2 Trial conducted to assess whether a starting dose of lenvatinib 14 milligrams (mg) in combination with everolimus 5 mg once daily (QD) will provide comparable efficacy (based on objective response rate [ORR] at 24 weeks [ORR24W]) with an improved safety profile compared to lenvatinib 18 mg in combination with everolimus 5 mg (based on treatment-emergent intolerable Grade 2, or any greater than or equal to (>=) Grade 3 adverse events (AEs) in the first 24 weeks after randomization).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least 1 measurable target lesion according to (RECIST 1.1) meeting the following criteria:
Adequate bone marrow function defined by:
Adequate liver function defined by:
Exclusion Criteria:
Females of who (Note: all females will be considered to be of childbearing potential unless they are [amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause] or have been sterilized surgically [that is, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing].):
do not agree to use a highly effective method of for the entire study period and for up to 8 weeks after study drug discontinuation, that is:
For sites outside of the European Union, it is permissible that if a highly effective method of contraception is not appropriate or acceptable to the participant, then the participant must agree to use a medically acceptable method of contraception, that is, double barrier methods of contraception, such as condom plus diaphragm or cervical/vault cap with spermicide.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral lenvatinib 14 mg once daily (QD) plus oral everolimus 5 mg QD as the starting dose for Cycle 1. If there are no intolerable Grade 2 or any \>= Grade 3 treatment-emergent adverse events (TEAEs) that require dose reduction in the first 28-day cycle (that is, the first 4 weeks of treatment), the lenvatinib dose will be escalated to 18 mg QD (plus everolimus 5 mg) beginning in Cycle 2 or later (cycle length equal to \[=\] 28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.
Drug: lenvatinib · Drug: everolimus
Participants will receive oral lenvatinib 18 mg QD plus oral everolimus 5 mg QD as the starting dose in Cycle 1 or later (cycle length =28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.
Drug: lenvatinib · Drug: everolimus
lenvatinib capsules.
everolimus tablets.
Objective Response Rate at Week 24 (ORR24W)
ORR24W was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) at the Week 24 (after randomization) time point, during treatment or within 28 days after the last dose date but on or prior to the start of new anticancer therapy based on investigator assessment according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10 millimeters (mm). PR: defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. To be considered a BOR, all responses had to be confirmed no less than 4 weeks after the initial assessment of response.
Time frame: At Week 24
Percentage of Participants With Intolerable Grade 2 or Any Grade >=Grade 3 TEAEs Within 24 Weeks
TEAE was defined as an adverse event (AE) with an onset that had occurred after receiving study drug. A severity grade was defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. As per NCI-CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE.
Time frame: Up to Week 24
Progression-free Survival (PFS)
PFS was defined as the time from the date of randomization to the date of the first documentation of PD by investigator assessment or date of death, whichever occurred first according to RECIST v1.1. PD: at least 20% increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameter (SOD) of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Median PFS was analyzed using the Kaplan-Meier product-limit estimates for each treatment group and presented with 2-sided 95% confidence interval (CI). As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.
Time frame: From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to date of data cutoff for the primary analysis (up to 29 months)
Objective Response Rate (ORR)
ORR was defined as the percentage of participants with a BOR of CR or PR at the at the end of treatment based on investigator assessment according to RECIST v1.1. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to \<10 mm. PR: defined as at least a 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. To be considered a BOR, all responses had to be confirmed no less than 4 weeks after the initial assessment of response. As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.
Time frame: From date of randomization up to first documentation of PD or date of death, whichever occurred first or up to the date of data cut off for the primary analysis (up to 29 months)
Number of Participants With TEAEs and Serious TEAEs
TEAEs were defined as those adverse events (AEs) that occurred (or worsened, if present at Baseline) after the first dose of study drug through 28 days after the last dose of study drug. An AE was defined as any untoward medical occurrence in a participants or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with medicinal product. A serious adverse event (SAE) was defined as any AE if it resulted in death or life-threatening AE or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions or was a congenital anomaly/birth defect.
Time frame: From date of first dose of study drug up to 28 days after last dose of study drug (up to 71 months)
Percentage of Participants Who Discontinued Treatment Due to Toxicity
Percentage of participants who discontinued treatment due to toxicity, defined as the percentage of participants who discontinued study treatment due to TEAEs. Toxicity (except hypertension and non-infectious pneumonitis) was assessed according to NCI-CTCAE v4.03.
Time frame: From date of first dose of study drug up to 28 days after last dose of study drug (up to 71 months)
Time to Treatment Failure Due to Toxicity
Time to treatment failure due to toxicity was defined as the time from the date of randomization to the date that a participant discontinued study treatment due to TEAEs. Toxicity (except hypertension and non-infectious pneumonitis) was assessed according to CTCAE v4.03. As planned, data for this secondary outcome measure was collected and analyzed till the primary analysis only.
Time frame: From the date of randomization to the date of discontinuation of study treatment due to TEAEs, or date of data cut off for the primary analysis (up to 29 months)
Plasma Concentration of Lenvatinib
PK sparse sampling was performed. As planned, the post-dose plasma sample was collected anytime between 0.5 to 4 hours at Cycle 1 Days 1 and 15, between 6 to 10 hours at Cycle 1 Days 1 and 15, and between 2 to 12 hours at Cycle 2 Day 1. Only one sample was collected for each post-dose category between specified timepoints.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)
Whole Blood Concentration of Everolimus
PK sparse sampling was performed. As planned, the post-dose whole blood sample was collected anytime between 0.5 to 4 hours at Cycle 1 Days 1 and 15, between 6 to 10 hours at Cycle 1 Days 1 and 15, and between 2 to 12 hours at Cycle 2 Day 1. Only one sample was collected for each post-dose category between specified timepoints.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)
Model Predicted Apparent Total Clearance (CL/F) for Lenvatinib Alone and When Coadministration With Everolimus in Renal Cell Carcinoma (RCC) Participants to Assess Drug-Drug Interaction
Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The lenvatinib concentration data was pooled from studies E7080 -G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) and from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for lenvatinib was fitted to the pooled dataset. Individual lenvatinib CL/F value was derived from the final PK model. The outcome measure was assessed for lenvatinib 18 mg dose only.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)
Model Predicted Dose Normalized Area Under the Plasma Concentration-time Curve (AUC) for Lenvatinib Alone and When Coadministration With Everolimus in RCC Participants to Assess Drug-Drug Interaction
Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The lenvatinib concentration data was pooled from studies E7080 -G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) and from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for lenvatinib was fitted to the pooled dataset. Individual lenvatinib AUC at steady state based on the starting dose was derived as a function of starting dose from the final PK model. The outcome measure was assessed for lenvatinib 18 mg dose only.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)
Model Predicted CL/F for Everolimus Alone and When Coadministration With Lenvatinib in RCC Participants to Assess Drug-Drug Interaction
Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The everolimus concentration data was pooled from studies E7080-G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) or from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for everolimus was fitted to the pooled dataset. Individual everolimus CL/F value was derived from the final PK model.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)
Model Predicted Dose Normalized AUC for Everolimus Alone and When Coadministration With Lenvatinib in RCC Participants to Assess Drug-Drug Interaction
Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The everolimus concentration data was pooled from studies E7080-G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) or from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for everolimus was fitted to the pooled dataset. Individual everolimus AUC at steady state based on the starting dose was derived as a function of starting dose from the final PK model.
Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: pre-dose and 2-12 hours post-dose (each cycle length =28 days)
Overall Survival (OS)
OS was defined as the time from the date of randomization until the date of death from any cause. In the absence of confirmation of death, participants will be censored either at the date that the participant was last known to be alive or the date of data cutoff for the primary analysis, whichever comes earlier. Median OS was to be calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval. As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.
Time frame: From the date of randomization until the date of death from any cause, or up to date of data cut off for the primary analysis (up to 29 months)
Health-Related Quality of Life (HRQoL) Assessed by Functional Assessment of Cancer Therapy Kidney Syndrome Index-Disease-Related Symptoms (FKSI-DRS) Scores
The FKSI-DRS consisted of 9 items that experts and participants had indicated are important targets for the treatment of advanced kidney cancer, and that clinical experts had indicated are primarily disease-related, as opposed to treatment-related. Symptoms assessed on the FKSI-DRS included lack of energy, fatigue, weight loss, pain, bone pain, shortness of breath, cough, fever, or hematuria. Each item was scored on a 5-point Likert-type scale (0 = not at all; 4 = very much) where total score ranged from 0 (worst) to 36 (best), where higher scores correspond to better outcomes. As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.
Time frame: At baseline (prior to first dose of study drug), on Day 1 of each subsequent cycle (cycle length =28 days), and at the Off-treatment visit (up to 29 months)
HRQoL Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Scores
The EORT QLQ-C30 consisted of 30 questions comprising 9 multiple-item scales and 6 single items. Multiple-item scales of QLQ-C30 consisted of 5 functional scales (physical, role, emotional, cognitive, and social) and 3 symptom scales (fatigue, nausea and vomiting, pain) and a global health status/QOL score. Six single-item scales of QLQ-C30 involved dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties. First 28 questions used a 4-point scale (1 = Not at all to 4 = Very much); and last 2 questions used a 7-point scale (1 = Very poor to 7 = Excellent). Scores for all scales range from 0 to 100. For the overall HRQoL and functioning scales, a higher score was correlated with better HRQoL, whereas a higher score for symptom scales represented worse HRQoL. As pre-specified in protocol, data for secondary outcome measure was collected and analyzed till primary analysis only.
Time frame: At baseline (prior to first dose of study drug), on Day 1 of each subsequent cycle (cycle length =28 days), and at the Off-treatment visit (up to 29 months)
HRQoL Assessed by European Quality of Life (EuroQol) Five-Dimensional, 3-Level (EQ-5D-3L) Index Score and Visual Analogue Scale (VAS)
The EQ-5D-3L is a health profile questionnaire assessing quality of life along 5 dimensions. Participants rate 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 5-15 with "5" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. The EQ-5D index was calculated by applying preference-based weights (tariffs) to the scores of the five health state dimensions. Index values can range from -1 to 1, with 0 representing a health state equivalent to death and 1 representing perfect health. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best).
Time frame: At baseline (prior to first dose of study drug), on Day 1 of each subsequent cycle (cycle length =28 days), and at the Off-treatment visit (up to 29 months)
Progression-free Survival After Next Line of Therapy (PFS2)
PFS2, defined as the time from randomization to the date of PD after next line of therapy or death from any cause, whichever occurred first based on investigator assessment according to RECIST v1.1. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Median PFS2 was analyzed using the Kaplan-Meier product-limit estimates for each treatment group and presented with 2-sided 95% CI. As pre-specified in protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.
Time frame: From the time of randomization to the date of PD after next line of therapy or death from any cause or the date of data cutoff for the primary analysis, whichever occurs first (up to 29 months)
Participants took part in the study at 82 investigative sites in Australia, Korea, Taiwan, Czech, Poland, Romania, Russia, Finland, Greece, Italy, Netherlands, Portugal, Spain, United Kingdom, Canada and the United States from 17 August 2017 to 20 June 2024.
| Milestone | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Started | 172 | 171 |
| Treated participants | 172 | 169 |
| Safety set | 173 | 168 |
| Completed | 91 | 101 |
| Not completed | 81 | 70 |
| Withdrew: Death | 70 | 60 |
| Withdrew: Lost to follow-up | 1 | 4 |
| Withdrew: Withdrawal by subject | 10 | 5 |
| Withdrew: Other | 0 | 1 |
ORR24W was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) at the Week 24 (after randomization) time point, during treatment or within 28 days after the last dose date but on or prior to the start of new anticancer therapy based on investigator assessment according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10 millimeters (mm). PR: defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. To be considered a BOR, all responses had to be confirmed no less than 4 weeks after the initial assessment of response.
| percentage of participants | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Objective Response Rate at Week 24 (ORR24W) | 32.1 (24.7 to 39.4) | 34.8 (27.3 to 42.3) |
TEAE was defined as an adverse event (AE) with an onset that had occurred after receiving study drug. A severity grade was defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. As per NCI-CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE.
| percentage of participants | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Percentage of Participants With Intolerable Grade 2 or Any Grade >=Grade 3 TEAEs Within 24 Weeks | 82.8 (76.9 to 88.7) | 79.6 (73.2 to 86.0) |
PFS was defined as the time from the date of randomization to the date of the first documentation of PD by investigator assessment or date of death, whichever occurred first according to RECIST v1.1. PD: at least 20% increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameter (SOD) of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Median PFS was analyzed using the Kaplan-Meier product-limit estimates for each treatment group and presented with 2-sided 95% confidence interval (CI). As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.
| months | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Progression-free Survival (PFS) | 11.1 (9.0 to 12.9) | 14.7 (11.1 to 20.3) |
ORR was defined as the percentage of participants with a BOR of CR or PR at the at the end of treatment based on investigator assessment according to RECIST v1.1. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to \<10 mm. PR: defined as at least a 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. To be considered a BOR, all responses had to be confirmed no less than 4 weeks after the initial assessment of response. As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.
| percentage of participants | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Objective Response Rate (ORR) | 34.6 (27.1 to 42.1) | 40.6 (32.9 to 48.4) |
TEAEs were defined as those adverse events (AEs) that occurred (or worsened, if present at Baseline) after the first dose of study drug through 28 days after the last dose of study drug. An AE was defined as any untoward medical occurrence in a participants or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with medicinal product. A serious adverse event (SAE) was defined as any AE if it resulted in death or life-threatening AE or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions or was a congenital anomaly/birth defect.
| Participants | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Participants With TEAEs | 173 | 167 |
| Participants With Serious TEAEs | 92 | 87 |
Percentage of participants who discontinued treatment due to toxicity, defined as the percentage of participants who discontinued study treatment due to TEAEs. Toxicity (except hypertension and non-infectious pneumonitis) was assessed according to NCI-CTCAE v4.03.
| percentage of participants | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Percentage of Participants Who Discontinued Treatment Due to Toxicity | 17.4 | 25.1 |
Time to treatment failure due to toxicity was defined as the time from the date of randomization to the date that a participant discontinued study treatment due to TEAEs. Toxicity (except hypertension and non-infectious pneumonitis) was assessed according to CTCAE v4.03. As planned, data for this secondary outcome measure was collected and analyzed till the primary analysis only.
| months | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Time to Treatment Failure Due to Toxicity | 3.15 (0.5 to 12.7) | 5.70 (0.8 to 24.6) |
PK sparse sampling was performed. As planned, the post-dose plasma sample was collected anytime between 0.5 to 4 hours at Cycle 1 Days 1 and 15, between 6 to 10 hours at Cycle 1 Days 1 and 15, and between 2 to 12 hours at Cycle 2 Day 1. Only one sample was collected for each post-dose category between specified timepoints.
| nanogram per milliliter (ng/mL) | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Cycle 1 Day 1: 0.5-4 hours post-dose | 57.9 ± 96.54 | 82.3 ± 119.89 |
| Cycle 1 Day 1: 6-10 hours post-dose | 136.3 ± 66.53 | 193.7 ± 93.08 |
| Cycle 1 Day 15: Pre-dose | 53.7 ± 62.31 | 64.0 ± 59.71 |
| Cycle 1 Day 15: 0.5-4 hours post-dose | 99.6 ± 102.54 | 133.4 ± 125.65 |
| Cycle 1 Day 15: 6-10 hours post-dose | 177.8 ± 89.42 | 236.2 ± 135.21 |
| Cycle 2 Day 1: Pre-dose | 42.8 ± 42.84 | 50.6 ± 46.06 |
| Cycle 2 Day 1: 2-12 hours post-dose | 172.8 ± 130.90 | 190.3 ± 114.85 |
PK sparse sampling was performed. As planned, the post-dose whole blood sample was collected anytime between 0.5 to 4 hours at Cycle 1 Days 1 and 15, between 6 to 10 hours at Cycle 1 Days 1 and 15, and between 2 to 12 hours at Cycle 2 Day 1. Only one sample was collected for each post-dose category between specified timepoints.
| ng/mL | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Cycle 1 Day 1: 0.5-4 hours post-dose | 18.3 ± 15.89 | 18.6 ± 16.39 |
| Cycle 1 Day 1: 6-10 hours post-dose | 9.2 ± 6.60 | 8.4 ± 5.64 |
| Cycle 1 Day 15: Pre-dose | 8.4 ± 4.84 | 7.4 ± 5.51 |
| Cycle 1 Day 15: 0.5-4 hours post-dose | 23.7 ± 15.41 | 23.4 ± 16.96 |
| Cycle 1 Day 15: 6-10 hours post-dose | 14.3 ± 5.83 | 14.3 ± 9.22 |
| Cycle 2 Day 1: Pre-dose | 7.8 ± 5.44 | 5.9 ± 4.02 |
| Cycle 2 Day 1: 2-12 hours post-dose | 22.9 ± 12.67 | 19.5 ± 9.74 |
Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The lenvatinib concentration data was pooled from studies E7080 -G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) and from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for lenvatinib was fitted to the pooled dataset. Individual lenvatinib CL/F value was derived from the final PK model. The outcome measure was assessed for lenvatinib 18 mg dose only.
| liter per hour (L/h) | Lenvatinib 18 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Model Predicted Apparent Total Clearance (CL/F) for Lenvatinib Alone and When Coadministration With Everolimus in Renal Cell Carcinoma (RCC) Participants to Assess Drug-Drug Interaction | 6.37 ± 2.01 | 5.77 ± 2.01 |
Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The lenvatinib concentration data was pooled from studies E7080 -G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) and from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for lenvatinib was fitted to the pooled dataset. Individual lenvatinib AUC at steady state based on the starting dose was derived as a function of starting dose from the final PK model. The outcome measure was assessed for lenvatinib 18 mg dose only.
| nanogram*hour per milliliter (ng*h/mL) | Lenvatinib 18 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Model Predicted Dose Normalized Area Under the Plasma Concentration-time Curve (AUC) for Lenvatinib Alone and When Coadministration With Everolimus in RCC Participants to Assess Drug-Drug Interaction | 3693 ± 1295 | 4350 ± 2934 |
Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The everolimus concentration data was pooled from studies E7080-G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) or from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for everolimus was fitted to the pooled dataset. Individual everolimus CL/F value was derived from the final PK model.
| liter per hour (L/h) | Everolimus 10 mg | Lenvatinib + Everolimus 5 mg |
|---|---|---|
| Model Predicted CL/F for Everolimus Alone and When Coadministration With Lenvatinib in RCC Participants to Assess Drug-Drug Interaction | 22.3 ± 10.5 | 19.4 ± 7.9 |
Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. The everolimus concentration data was pooled from studies E7080-G000-205 (NCT01136733), E7080-M001-221 (NCT02915783), E7080-J081-112 (NCT02454478) or from current study E7080-G000-218 (NCT03173560). A previously developed 3-compartment PK model for everolimus was fitted to the pooled dataset. Individual everolimus AUC at steady state based on the starting dose was derived as a function of starting dose from the final PK model.
| ng*hour/mL | Everolimus 10 mg | Lenvatinib + Everolimus 5 mg |
|---|---|---|
| Model Predicted Dose Normalized AUC for Everolimus Alone and When Coadministration With Lenvatinib in RCC Participants to Assess Drug-Drug Interaction | 507.4 ± 176.6 | 305.5 ± 174.0 |
OS was defined as the time from the date of randomization until the date of death from any cause. In the absence of confirmation of death, participants will be censored either at the date that the participant was last known to be alive or the date of data cutoff for the primary analysis, whichever comes earlier. Median OS was to be calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval. As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.
| months | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Overall Survival (OS) | 27.0 (18.3 to NA) | NA (23.8 to NA) |
The FKSI-DRS consisted of 9 items that experts and participants had indicated are important targets for the treatment of advanced kidney cancer, and that clinical experts had indicated are primarily disease-related, as opposed to treatment-related. Symptoms assessed on the FKSI-DRS included lack of energy, fatigue, weight loss, pain, bone pain, shortness of breath, cough, fever, or hematuria. Each item was scored on a 5-point Likert-type scale (0 = not at all; 4 = very much) where total score ranged from 0 (worst) to 36 (best), where higher scores correspond to better outcomes. As pre-specified in the protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.
| score on a scale | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Baseline | 29.69 ± 4.819 | 29 ± 5.886 |
| Cycle 2 Day 1 | 28.43 ± 5.269 | 28.31 ± 5.162 |
| Cycle 3 Day 1 | 28.26 ± 5.344 | 28.80 ± 5.455 |
| Cycle 4 Day 1 | 27.97 ± 5.524 | 29.11 ± 5.183 |
| Cycle 5 Day 1 | 28 ± 5.680 | 29.14 ± 5.081 |
| Cycle 6 Day 1 | 28.63 ± 5.185 | 29.46 ± 5.107 |
| Cycle 7 Day 1 | 28.31 ± 5.486 | 29.58 ± 4.803 |
| Cycle 8 Day 1 | 28.36 ± 6.204 | 29.85 ± 4.610 |
| Cycle 9 Day 1 | 28.58 ± 5.562 | 29.84 ± 5.005 |
| Cycle 10 Day 1 | 29.10 ± 5.294 | 30.70 ± 4.297 |
| Cycle 11 Day 1 | 29.56 ± 5.035 | 30.09 ± 5.316 |
| Cycle 12 Day 1 | 29.34 ± 5.149 | 30.75 ± 5.127 |
| Cycle 13 Day 1 | 29.26 ± 4.851 | 30.93 ± 4.201 |
| Cycle 14 Day 1 | 29.81 ± 4.752 | 31.06 ± 4.830 |
| Cycle 15 Day 1 | 30.09 ± 5.121 | 30.52 ± 4.417 |
| Cycle 16 Day 1 | 29.93 ± 5.293 | 30.91 ± 4.704 |
| Cycle 17 Day 1 | 29.36 ± 5.233 | 31.52 ± 4.875 |
| Cycle 18 Day 1 | 29.81 ± 4.293 | 31.41 ± 4.639 |
| Cycle 19 Day 1 | 28.48 ± 6.216 | 30.82 ± 4.469 |
| Cycle 20 Day 1 | 28.77 ± 6.058 | 30.69 ± 4.575 |
| Cycle 21 Day 1 | 29.35 ± 4.707 | 32 ± 3.243 |
| Cycle 22 Day 1 | 30.32 ± 4.978 | 30.59 ± 5.168 |
| Cycle 23 Day 1 | 30.53 ± 3.998 | 30.29 ± 5.544 |
| Cycle 24 Day 1 | 29.47 ± 5.041 | 31.58 ± 3.977 |
| Cycle 25 Day 1 | 27.92 ± 6.388 | 31.69 ± 4.270 |
| Cycle 26 Day 1 | 28.75 ± 4.862 | 29.82 ± 6.422 |
| Cycle 27 Day 1 | 29.83 ± 5.345 | 32.86 ± 2.854 |
| Cycle 28 Day 1 | 30.50 ± 4.435 | 33.67 ± 1.862 |
| Cycle 29 Day 1 | 29.50 ± 4.359 | 33.40 ± 1.342 |
| Cycle 30 Day 1 | 30.75 ± 4.031 | 36 |
| Cycle 31 Day 1 | 31 | — |
| Off-treatment Visit | 27.42 ± 5.953 | 27.86 ± 6.500 |
The EORT QLQ-C30 consisted of 30 questions comprising 9 multiple-item scales and 6 single items. Multiple-item scales of QLQ-C30 consisted of 5 functional scales (physical, role, emotional, cognitive, and social) and 3 symptom scales (fatigue, nausea and vomiting, pain) and a global health status/QOL score. Six single-item scales of QLQ-C30 involved dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties. First 28 questions used a 4-point scale (1 = Not at all to 4 = Very much); and last 2 questions used a 7-point scale (1 = Very poor to 7 = Excellent). Scores for all scales range from 0 to 100. For the overall HRQoL and functioning scales, a higher score was correlated with better HRQoL, whereas a higher score for symptom scales represented worse HRQoL. As pre-specified in protocol, data for secondary outcome measure was collected and analyzed till primary analysis only.
| score on a scale | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Global Health Status/QoL Score; Baseline | 63.35 ± 22.020 | 63.58 ± 21.340 |
| Global Health Status/QoL Score; Cycle 2 Day 1 | 58.60 ± 21.234 | 60.93 ± 20.280 |
| Global Health Status/QoL Score; Cycle 3 Day 1 | 56.43 ± 24.065 | 61.85 ± 20.202 |
| Global Health Status/QoL Score; Cycle 4 Day 1 | 58.71 ± 19.754 | 62.62 ± 19.641 |
| Global Health Status/QoL Score; Cycle 5 Day 1 | 59.38 ± 21.670 | 63.76 ± 20.339 |
| Global Health Status/QoL Score; Cycle 6 Day 1 | 58.75 ± 21.028 | 63.73 ± 19.756 |
| Global Health Status/QoL Score; Cycle 7 Day 1 | 58.72 ± 20.134 | 62.54 ± 20.153 |
| Global Health Status/QoL Score; Cycle 8 Day 1 | 58.68 ± 20.409 | 62.11 ± 20.271 |
| Global Health Status/QoL Score; Cycle 9 Day 1 | 58.97 ± 18.726 | 63.77 ± 20.429 |
| Global Health Status/QoL Score; Cycle 10 Day 1 | 63.13 ± 19.612 | 66.44 ± 19.012 |
| Global Health Status/QoL Score; Cycle 11 Day 1 | 60.87 ± 18.705 | 65.86 ± 21.173 |
| Global Health Status/QoL Score; Cycle 12 Day 1 | 57.81 ± 18.891 | 66.94 ± 18.409 |
| Global Health Status/QoL Score; Cycle 13 Day 1 | 59.39 ± 19.047 | 68.94 ± 18.388 |
| Global Health Status/QoL Score; Cycle 14 Day 1 | 61.56 ± 17.498 | 70.35 ± 15.605 |
| Global Health Status/QoL Score; Cycle 15 Day 1 | 62.98 ± 16.795 | 66.83 ± 16.955 |
| Global Health Status/QoL Score; Cycle 16 Day 1 | 61.59 ± 17.567 | 64.54 ± 19.386 |
| Global Health Status/QoL Score; Cycle 17 Day 1 | 60.88 ± 16.882 | 67.71 ± 18.794 |
| Global Health Status/QoL Score; Cycle 18 Day 1 | 59.68 ± 16.258 | 68.38 ± 17.859 |
| Global Health Status/QoL Score; Cycle 19 Day 1 | 58.33 ± 19.747 | 66.67 ± 15.215 |
| Global Health Status/QoL Score; Cycle 20 Day 1 | 58.95 ± 18.479 | 66.40 ± 15.736 |
| Global Health Status/QoL Score; Cycle 21 Day 1 | 57.05 ± 18.362 | 71.13 ± 15.463 |
| Global Health Status/QoL Score; Cycle 22 Day 1 | 62.72 ± 14.532 | 66.05 ± 17.438 |
| Global Health Status/QoL Score; Cycle 23 Day 1 | 60 ± 15.494 | 66.67 ± 14.948 |
| Global Health Status/QoL Score; Cycle 24 Day 1 | 64.44 ± 17.385 | 65.79 ± 18.818 |
| Global Health Status/QoL Score; Cycle 25 Day 1 | 58.33 ± 16.667 | 69.79 ± 14.868 |
| Global Health Status/QoL Score; Cycle 26 Day 1 | 59.38 ± 15.064 | 60.90 ± 18.442 |
| Global Health Status/QoL Score; Cycle 27 Day 1 | 59.72 ± 18.572 | 71.43 ± 18.545 |
| Global Health Status/QoL Score; Cycle 28 Day 1 | 58.33 ± 21.517 | 77.78 ± 13.608 |
| Global Health Status/QoL Score; Cycle 29 Day 1 | 56.25 ± 18.478 | 75 ± 16.667 |
| Global Health Status/QoL Score; Cycle 30 Day 1 | 54.17 ± 15.957 | 66.67 |
| Global Health Status/QoL Score; Cycle 31 Day 1 | 33.33 | — |
| Global Health Status/QoL Score; Off-treatment Visit | 51.04 ± 23.133 | 56.05 ± 22.363 |
| Physical Functioning Score; Baseline | 76.36 ± 19.282 | 76.60 ± 21.855 |
| Physical Functioning Score; Cycle 2 Day 1 | 73.54 ± 19.857 | 75.38 ± 19.706 |
| Physical Functioning Score; Cycle 3 Day 1 | 72.74 ± 21.227 | 76.15 ± 19.160 |
| Physical Functioning Score; Cycle 4 Day 1 | 70.90 ± 20.873 | 75.40 ± 20.155 |
| Physical Functioning Score; Cycle 5 Day 1 | 72.80 ± 19.284 | 77.85 ± 18.342 |
| Physical Functioning Score; Cycle 6 Day 1 | 72.17 ± 21.694 | 77.76 ± 18.562 |
| Physical Functioning Score; Cycle 7 Day 1 | 73.02 ± 20.769 | 78.41 ± 18.034 |
| Physical Functioning Score; Cycle 8 Day 1 | 72.77 ± 20.422 | 79.11 ± 17.707 |
| Physical Functioning Score; Cycle 9 Day 1 | 74.54 ± 19.389 | 80.60 ± 16.041 |
| Physical Functioning Score; Cycle 10 Day 1 | 75.06 ± 18.908 | 81.20 ± 16.271 |
| Physical Functioning Score; Cycle 11 Day 1 | 73.72 ± 18.073 | 81.13 ± 16.638 |
| Physical Functioning Score; Cycle 12 Day 1 | 75.52 ± 17.080 | 83.01 ± 15.254 |
| Physical Functioning Score; Cycle 13 Day 1 | 74.55 ± 17.874 | 80.24 ± 16.873 |
| Physical Functioning Score; Cycle 14 Day 1 | 75.78 ± 16.925 | 82.39 ± 16.387 |
| Physical Functioning Score; Cycle 15 Day 1 | 75.45 ± 16.629 | 80.92 ± 17.283 |
| Physical Functioning Score; Cycle 16 Day 1 | 73.46 ± 17.129 | 81.74 ± 15.982 |
| Physical Functioning Score; Cycle 17 Day 1 | 71.85 ± 17.896 | 82.33 ± 15.657 |
| Physical Functioning Score; Cycle 18 Day 1 | 75.48 ± 17.838 | 81.52 ± 16.135 |
| Physical Functioning Score; Cycle 19 Day 1 | 76.67 ± 15.771 | 81.57 ± 16.002 |
| Physical Functioning Score; Cycle 20 Day 1 | 73.09 ± 22.071 | 82.80 ± 13.854 |
| Physical Functioning Score; Cycle 21 Day 1 | 74.62 ± 18.668 | 84.29 ± 12.335 |
| Physical Functioning Score; Cycle 22 Day 1 | 80.35 ± 14.483 | 82.72 ± 15.164 |
| Physical Functioning Score; Cycle 23 Day 1 | 79.56 ± 14.357 | 81.39 ± 17.248 |
| Physical Functioning Score; Cycle 24 Day 1 | 77.33 ± 16.676 | 83.86 ± 13.755 |
| Physical Functioning Score; Cycle 25 Day 1 | 72.78 ± 15.688 | 84.17 ± 15.753 |
| Physical Functioning Score; Cycle 26 Day 1 | 76.67 ± 6.172 | 71.79 ± 29.833 |
| Physical Functioning Score; Cycle 27 Day 1 | 76.67 ± 6.992 | 85.71 ± 16.523 |
| Physical Functioning Score; Cycle 28 Day 1 | 78.33 ± 3.333 | 90 ± 15.635 |
| Physical Functioning Score; Cycle 29 Day 1 | 78.33 ± 3.333 | 86.67 ± 16.330 |
| Physical Functioning Score; Cycle 30 Day 1 | 76.67 ± 3.849 | 100 |
| Physical Functioning Score; Cycle 31 Day 1 | 80 | — |
| Physical Functioning Score; Off-treatment Visit | 64.50 ± 25.891 | 70.41 ± 25.139 |
| Role Functioning Score; Baseline | 73.78 ± 27.471 | 75.72 ± 27.932 |
| Role Functioning Score; Cycle 2 Day 1 | 68.25 ± 27.951 | 69.33 ± 27.449 |
| Role Functioning Score; Cycle 3 Day 1 | 67 ± 28.136 | 72.18 ± 25.630 |
| Role Functioning Score; Cycle 4 Day 1 | 66.67 ± 27.993 | 73.60 ± 26.169 |
| Role Functioning Score; Cycle 5 Day 1 | 67.32 ± 28.479 | 72.44 ± 25.143 |
| Role Functioning Score; Cycle 6 Day 1 | 68.16 ± 27.245 | 73.75 ± 27.557 |
| Role Functioning Score; Cycle 7 Day 1 | 66.51 ± 27.424 | 73.97 ± 25.205 |
| Role Functioning Score; Cycle 8 Day 1 | 68.20 ± 27.712 | 75.60 ± 26.139 |
| Role Functioning Score; Cycle 9 Day 1 | 67.58 ± 26.101 | 75.91 ± 25.242 |
| Role Functioning Score; Cycle 10 Day 1 | 68.52 ± 27.131 | 76.89 ± 24.027 |
| Role Functioning Score; Cycle 11 Day 1 | 69.57 ± 25.237 | 79.11 ± 23.691 |
| Role Functioning Score; Cycle 12 Day 1 | 70.51 ± 24.785 | 80.91 ± 22.953 |
| Role Functioning Score; Cycle 13 Day 1 | 69.64 ± 24.434 | 80 ± 24.721 |
| Role Functioning Score; Cycle 14 Day 1 | 71.09 ± 24.242 | 81.13 ± 23.121 |
| Role Functioning Score; Cycle 15 Day 1 | 72.73 ± 22.184 | 74.84 ± 25.685 |
| Role Functioning Score; Cycle 16 Day 1 | 70.33 ± 23.426 | 79.08 ± 21.272 |
| Role Functioning Score; Cycle 17 Day 1 | 65.74 ± 22.868 | 83.75 ± 18.292 |
| Role Functioning Score; Cycle 18 Day 1 | 67.74 ± 20.609 | 82.35 ± 22.073 |
| Role Functioning Score; Cycle 19 Day 1 | 67.28 ± 28.300 | 77.45 ± 23.883 |
| Role Functioning Score; Cycle 20 Day 1 | 70.37 ± 23.266 | 79.57 ± 24.612 |
| Role Functioning Score; Cycle 21 Day 1 | 69.23 ± 21.956 | 81.55 ± 19.948 |
| Role Functioning Score; Cycle 22 Day 1 | 75.44 ± 20.313 | 77.78 ± 22.169 |
| Role Functioning Score; Cycle 23 Day 1 | 73.33 ± 25.040 | 79.86 ± 23.560 |
| Role Functioning Score; Cycle 24 Day 1 | 78.89 ± 16.019 | 83.33 ± 19.245 |
| Role Functioning Score; Cycle 25 Day 1 | 77.78 ± 17.885 | 82.29 ± 23.936 |
| Role Functioning Score; Cycle 26 Day 1 | 75 ± 12.599 | 69.23 ± 31.066 |
| Role Functioning Score; Cycle 27 Day 1 | 77.78 ± 13.608 | 90.48 ± 16.265 |
| Role Functioning Score; Cycle 28 Day 1 | 79.17 ± 15.957 | 97.22 ± 6.804 |
| Role Functioning Score; Cycle 29 Day 1 | 75 ± 9.623 | 96.67 ± 7.454 |
| Role Functioning Score; Cycle 30 Day 1 | 87.50 ± 15.957 | 100 |
| Role Functioning Score; Cycle 31 Day 1 | 66.67 | — |
| Role Functioning Score; Off-treatment Visit | 60.97 ± 31.790 | 63.51 ± 31.656 |
| Emotional Functioning Score; Baseline | 79.35 ± 19.704 | 80.06 ± 19.729 |
| Emotional Functioning Score; Cycle 2 Day 1 | 79.41 ± 19.465 | 82.06 ± 19.167 |
| Emotional Functioning Score; Cycle 3 Day 1 | 78.47 ± 21.642 | 82.90 ± 19.314 |
| Emotional Functioning Score; Cycle 4 Day 1 | 78.26 ± 18.854 | 84.19 ± 18.517 |
| Emotional Functioning Score; Cycle 5 Day 1 | 75.85 ± 21.767 | 84.52 ± 15.766 |
| Emotional Functioning Score; Cycle 6 Day 1 | 80.60 ± 18.703 | 84.38 ± 18.365 |
| Emotional Functioning Score; Cycle 7 Day 1 | 77.18 ± 19.571 | 84.29 ± 16.356 |
| Emotional Functioning Score; Cycle 8 Day 1 | 79.08 ± 19.744 | 84.88 ± 18.215 |
| Emotional Functioning Score; Cycle 9 Day 1 | 78.75 ± 22.127 | 85.96 ± 17.512 |
| Emotional Functioning Score; Cycle 10 Day 1 | 80.04 ± 19.440 | 87.84 ± 15.433 |
| Emotional Functioning Score; Cycle 11 Day 1 | 82.25 ± 20.558 | 87.15 ± 16.247 |
| Emotional Functioning Score; Cycle 12 Day 1 | 81.51 ± 19.157 | 86.67 ± 15.358 |
| Emotional Functioning Score; Cycle 13 Day 1 | 79.32 ± 17.908 | 87.27 ± 15.783 |
| Emotional Functioning Score; Cycle 14 Day 1 | 81.35 ± 16.782 | 87.50 ± 17.110 |
| Emotional Functioning Score; Cycle 15 Day 1 | 80.30 ± 18.336 | 87.25 ± 15.398 |
| Emotional Functioning Score; Cycle 16 Day 1 | 81.50 ± 17.432 | 87.41 ± 14.935 |
| Emotional Functioning Score; Cycle 17 Day 1 | 79.63 ± 19.664 | 87.08 ± 16.118 |
| Emotional Functioning Score; Cycle 18 Day 1 | 81.90 ± 15.330 | 86.76 ± 16.555 |
| Emotional Functioning Score; Cycle 19 Day 1 | 81.17 ± 15.945 | 84.80 ± 18.403 |
| Emotional Functioning Score; Cycle 20 Day 1 | 80.25 ± 17.925 | 86.56 ± 17.437 |
| Emotional Functioning Score; Cycle 21 Day 1 | 81.73 ± 15.279 | 88.99 ± 14.174 |
| Emotional Functioning Score; Cycle 22 Day 1 | 85.09 ± 16.096 | 89.20 ± 15.644 |
| Emotional Functioning Score; Cycle 23 Day 1 | 86.67 ± 15.366 | 87.15 ± 15.922 |
| Emotional Functioning Score; Cycle 24 Day 1 | 88.89 ± 14.319 | 87.28 ± 13.712 |
| Emotional Functioning Score; Cycle 25 Day 1 | 83.33 ± 18.119 | 90.63 ± 12.500 |
| Emotional Functioning Score; Cycle 26 Day 1 | 77.08 ± 23.038 | 85.26 ± 23.362 |
| Emotional Functioning Score; Cycle 27 Day 1 | 80.56 ± 16.387 | 95.24 ± 12.599 |
| Emotional Functioning Score; Cycle 28 Day 1 | 75 ± 16.667 | 100 ± 0 |
| Emotional Functioning Score; Cycle 29 Day 1 | 75 ± 16.667 | 100 ± 0 |
| Emotional Functioning Score; Cycle 30 Day 1 | 75 ± 16.667 | 100 |
| Emotional Functioning Score; Cycle 31 Day 1 | 66.67 | — |
| Emotional Functioning Score; Off-treatment Visit | 69.62 ± 27.304 | 73.87 ± 25.145 |
| Cognitive Functioning Score; Baseline | 87.91 ± 15.764 | 89.51 ± 15.529 |
| Cognitive Functioning Score; Cycle 2 Day 1 | 87.15 ± 15.661 | 88.85 ± 18.025 |
| Cognitive Functioning Score; Cycle 3 Day 1 | 84.45 ± 19.049 | 87.47 ± 17.946 |
| Cognitive Functioning Score; Cycle 4 Day 1 | 83.58 ± 19.461 | 90.32 ± 13.692 |
| Cognitive Functioning Score; Cycle 5 Day 1 | 83.99 ± 17.239 | 87.43 ± 17.086 |
| Cognitive Functioning Score; Cycle 6 Day 1 | 84.71 ± 16.886 | 87.68 ± 18.470 |
| Cognitive Functioning Score; Cycle 7 Day 1 | 82.40 ± 18.855 | 87.94 ± 14.708 |
| Cognitive Functioning Score; Cycle 8 Day 1 | 81.97 ± 21.227 | 88.49 ± 16.380 |
| Cognitive Functioning Score; Cycle 9 Day 1 | 83.70 ± 18.084 | 87.68 ± 17.095 |
| Cognitive Functioning Score; Cycle 10 Day 1 | 85.39 ± 17.947 | 90.44 ± 13.747 |
| Cognitive Functioning Score; Cycle 11 Day 1 | 84.06 ± 18.176 | 88.89 ± 15.824 |
| Cognitive Functioning Score; Cycle 12 Day 1 | 85.42 ± 16.400 | 88.61 ± 17.758 |
| Cognitive Functioning Score; Cycle 13 Day 1 | 83.93 ± 17.685 | 89.70 ± 12.624 |
| Cognitive Functioning Score; Cycle 14 Day 1 | 85.71 ± 18.634 | 87.18 ± 16.375 |
| Cognitive Functioning Score; Cycle 15 Day 1 | 84.85 ± 18.264 | 83.99 ± 17.308 |
| Cognitive Functioning Score; Cycle 16 Day 1 | 83.74 ± 18.062 | 89.36 ± 13.649 |
| Cognitive Functioning Score; Cycle 17 Day 1 | 82.87 ± 18.033 | 89.58 ± 14.465 |
| Cognitive Functioning Score; Cycle 18 Day 1 | 83.87 ± 17.994 | 90.20 ± 15.417 |
| Cognitive Functioning Score; Cycle 19 Day 1 | 80.25 ± 18.511 | 89.22 ± 14.727 |
| Cognitive Functioning Score; Cycle 20 Day 1 | 82.10 ± 17.250 | 91.94 ± 12.073 |
| Cognitive Functioning Score; Cycle 21 Day 1 | 81.41 ± 19.623 | 88.10 ± 12.715 |
| Cognitive Functioning Score; Cycle 22 Day 1 | 88.60 ± 14.754 | 90.12 ± 12.454 |
| Cognitive Functioning Score; Cycle 23 Day 1 | 83.33 ± 16.667 | 88.19 ± 14.311 |
| Cognitive Functioning Score; Cycle 24 Day 1 | 84.44 ± 16.019 | 92.11 ± 8.550 |
| Cognitive Functioning Score; Cycle 25 Day 1 | 84.72 ± 15.006 | 98.96 ± 4.167 |
| Cognitive Functioning Score; Cycle 26 Day 1 | 89.58 ± 12.400 | 92.31 ± 11.004 |
| Cognitive Functioning Score; Cycle 27 Day 1 | 83.33 ± 14.907 | 95.24 ± 12.599 |
| Cognitive Functioning Score; Cycle 28 Day 1 | 91.67 ± 9.623 | 100 ± 0 |
| Cognitive Functioning Score; Cycle 29 Day 1 | 91.67 ± 9.623 | 100 ± 0 |
| Cognitive Functioning Score; Cycle 30 Day 1 | 87.50 ± 15.957 | 100 |
| Cognitive Functioning Score; Cycle 31 Day 1 | 83.33 | — |
| Cognitive Functioning Score; Off-treatment Visit | 75.21 ± 25.846 | 80.41 ± 23.304 |
| Social Functioning Score; Baseline | 77.29 ± 25.678 | 78.29 ± 27.243 |
| Social Functioning Score; Cycle 2 Day 1 | 73.46 ± 25.386 | 77.15 ± 27.190 |
| Social Functioning Score; Cycle 3 Day 1 | 72.04 ± 26.229 | 77.19 ± 25.309 |
| Social Functioning Score; Cycle 4 Day 1 | 71.43 ± 24.837 | 77.33 ± 25.311 |
| Social Functioning Score; Cycle 5 Day 1 | 71.78 ± 25.589 | 79.63 ± 23.934 |
| Social Functioning Score; Cycle 6 Day 1 | 70.80 ± 26.812 | 78.71 ± 25.758 |
| Social Functioning Score; Cycle 7 Day 1 | 71.70 ± 26.544 | 77.30 ± 24.691 |
| Social Functioning Score; Cycle 8 Day 1 | 70.24 ± 28.139 | 79.04 ± 24.565 |
| Social Functioning Score; Cycle 9 Day 1 | 72.16 ± 25.946 | 78.62 ± 20.573 |
| Social Functioning Score; Cycle 10 Day 1 | 72.43 ± 28.156 | 85.14 ± 19.422 |
| Social Functioning Score; Cycle 11 Day 1 | 73.91 ± 25.801 | 85.19 ± 19.086 |
| Social Functioning Score; Cycle 12 Day 1 | 76.56 ± 24.073 | 83.89 ± 23.161 |
| Social Functioning Score; Cycle 13 Day 1 | 72.92 ± 23.476 | 83.94 ± 21.508 |
| Social Functioning Score; Cycle 14 Day 1 | 72.79 ± 22.997 | 83.97 ± 19.792 |
| Social Functioning Score; Cycle 15 Day 1 | 72.73 ± 25.942 | 81.37 ± 22.273 |
| Social Functioning Score; Cycle 16 Day 1 | 73.17 ± 24.403 | 80.80 ± 22.489 |
| Social Functioning Score; Cycle 17 Day 1 | 70.37 ± 22.222 | 80.42 ± 24.134 |
| Social Functioning Score; Cycle 18 Day 1 | 76.88 ± 20.493 | 82.84 ± 21.116 |
| Social Functioning Score; Cycle 19 Day 1 | 74.07 ± 22.329 | 80.88 ± 25.667 |
| Social Functioning Score; Cycle 20 Day 1 | 75.31 ± 24.183 | 81.72 ± 22.092 |
| Social Functioning Score; Cycle 21 Day 1 | 73.72 ± 18.362 | 82.14 ± 24.398 |
| Social Functioning Score; Cycle 22 Day 1 | 79.82 ± 17.194 | 82.10 ± 20.634 |
| Social Functioning Score; Cycle 23 Day 1 | 82.22 ± 18.330 | 83.33 ± 22.522 |
| Social Functioning Score; Cycle 24 Day 1 | 83.33 ± 17.817 | 84.21 ± 19.621 |
| Social Functioning Score; Cycle 25 Day 1 | 87.50 ± 12.563 | 84.38 ± 18.727 |
| Social Functioning Score; Cycle 26 Day 1 | 83.33 ± 15.430 | 76.92 ± 31.578 |
| Social Functioning Score; Cycle 27 Day 1 | 80.56 ± 12.546 | 95.24 ± 12.599 |
| Social Functioning Score; Cycle 28 Day 1 | 83.33 ± 19.245 | 100 ± 0 |
| Social Functioning Score; Cycle 29 Day 1 | 79.17 ± 15.957 | 100 ± 0 |
| Social Functioning Score; Cycle 30 Day 1 | 70.83 ± 8.333 | 100 |
| Social Functioning Score; Cycle 31 Day 1 | 100 | — |
| Social Functioning Score; Off-treatment Visit | 64.58 ± 31.419 | 66.89 ± 32.453 |
| Fatigue Score; Baseline | 31.32 ± 21.379 | 31.76 ± 25.224 |
| Fatigue Score; Cycle 2 Day 1 | 39.21 ± 22.171 | 36.74 ± 23.665 |
| Fatigue Score; Cycle 3 Day 1 | 40.09 ± 24.095 | 36.62 ± 24.031 |
| Fatigue Score; Cycle 4 Day 1 | 40.21 ± 23.504 | 32.68 ± 23.829 |
| Fatigue Score; Cycle 5 Day 1 | 37.54 ± 23.329 | 35.17 ± 22.431 |
| Fatigue Score; Cycle 6 Day 1 | 38.80 ± 23.246 | 33.19 ± 23.696 |
| Fatigue Score; Cycle 7 Day 1 | 38.06 ± 21.850 | 30.79 ± 21.859 |
| Fatigue Score; Cycle 8 Day 1 | 36.14 ± 22.852 | 30.81 ± 23.268 |
| Fatigue Score; Cycle 9 Day 1 | 35.90 ± 21.281 | 30.80 ± 21.293 |
| Fatigue Score; Cycle 10 Day 1 | 34.57 ± 22.635 | 27.11 ± 20.278 |
| Fatigue Score; Cycle 11 Day 1 | 32.37 ± 20.851 | 27.46 ± 22.788 |
| Fatigue Score; Cycle 12 Day 1 | 32.82 ± 20.264 | 23.48 ± 21.302 |
| Fatigue Score; Cycle 13 Day 1 | 35.52 ± 18.882 | 25.05 ± 21.300 |
| Fatigue Score; Cycle 14 Day 1 | 30.84 ± 21.429 | 25.58 ± 20.276 |
| Fatigue Score; Cycle 15 Day 1 | 28.03 ± 20.682 | 28.98 ± 23.315 |
| Fatigue Score; Cycle 16 Day 1 | 33.33 ± 22.361 | 25.53 ± 20.581 |
| Fatigue Score; Cycle 17 Day 1 | 33.33 ± 21.902 | 25 ± 20.090 |
| Fatigue Score; Cycle 18 Day 1 | 34.05 ± 22.024 | 24.84 ± 19.546 |
| Fatigue Score; Cycle 19 Day 1 | 37.04 ± 23.061 | 27.45 ± 22.595 |
| Fatigue Score; Cycle 20 Day 1 | 34.57 ± 19.812 | 27.24 ± 22.192 |
| Fatigue Score; Cycle 21 Day 1 | 34.19 ± 20.828 | 23.02 ± 17.088 |
| Fatigue Score; Cycle 22 Day 1 | 26.32 ± 18.596 | 26.75 ± 20.033 |
| Fatigue Score; Cycle 23 Day 1 | 26.67 ± 20.053 | 29.17 ± 21.934 |
| Fatigue Score; Cycle 24 Day 1 | 28.15 ± 20.082 | 26.90 ± 17.496 |
| Fatigue Score; Cycle 25 Day 1 | 33.33 ± 19.534 | 25.69 ± 19.338 |
| Fatigue Score; Cycle 26 Day 1 | 26.39 ± 17.755 | 37.61 ± 28.160 |
| Fatigue Score; Cycle 27 Day 1 | 27.78 ± 16.851 | 20.63 ± 20.716 |
| Fatigue Score; Cycle 28 Day 1 | 22.22 ± 15.713 | 16.67 ± 19.563 |
| Fatigue Score; Cycle 29 Day 1 | 22.22 ± 15.713 | 15.56 ± 14.907 |
| Fatigue Score; Cycle 30 Day 1 | 25 ± 16.667 | 11.11 |
| Fatigue Score; Cycle 31 Day 1 | 33.33 | — |
| Fatigue Score; Off-treatment Visit | 43.47 ± 28.173 | 38.89 ± 28.977 |
| Nausea and Vomiting Score; Baseline | 7.60 ± 17.265 | 6.28 ± 14.510 |
| Nausea and Vomiting Score; Cycle 2 Day 1 | 11.50 ± 18.229 | 9.56 ± 17.943 |
| Nausea and Vomiting Score; Cycle 3 Day 1 | 14.86 ± 24.057 | 9.74 ± 18.219 |
| Nausea and Vomiting Score; Cycle 4 Day 1 | 15.80 ± 21.386 | 12.17 ± 18.906 |
| Nausea and Vomiting Score; Cycle 5 Day 1 | 12.07 ± 17.017 | 11.42 ± 18.270 |
| Nausea and Vomiting Score; Cycle 6 Day 1 | 12.74 ± 19.215 | 10.14 ± 18.996 |
| Nausea and Vomiting Score; Cycle 7 Day 1 | 12.46 ± 18.612 | 8.57 ± 13.696 |
| Nausea and Vomiting Score; Cycle 8 Day 1 | 13.10 ± 21.836 | 10.14 ± 15.508 |
| Nausea and Vomiting Score; Cycle 9 Day 1 | 12.27 ± 20.005 | 9.96 ± 17.306 |
| Nausea and Vomiting Score; Cycle 10 Day 1 | 15.02 ± 22.299 | 7.78 ± 16.287 |
| Nausea and Vomiting Score; Cycle 11 Day 1 | 11.11 ± 18.002 | 8.69 ± 15.394 |
| Nausea and Vomiting Score; Cycle 12 Day 1 | 12.82 ± 19.042 | 6.99 ± 14.645 |
| Nausea and Vomiting Score; Cycle 13 Day 1 | 12.20 ± 18.934 | 6.97 ± 13.867 |
| Nausea and Vomiting Score; Cycle 14 Day 1 | 14.97 ± 21.849 | 7.55 ± 16.527 |
| Nausea and Vomiting Score; Cycle 15 Day 1 | 14.02 ± 20.631 | 8.82 ± 15.038 |
| Nausea and Vomiting Score; Cycle 16 Day 1 | 11.38 ± 19.874 | 9.22 ± 15.467 |
| Nausea and Vomiting Score; Cycle 17 Day 1 | 14.35 ± 22.940 | 5 ± 13.183 |
| Nausea and Vomiting Score; Cycle 18 Day 1 | 10.75 ± 22.587 | 9.31 ± 15.457 |
| Nausea and Vomiting Score; Cycle 19 Day 1 | 16.67 ± 27.347 | 7.35 ± 15.457 |
| Nausea and Vomiting Score; Cycle 20 Day 1 | 16.67 ± 23.113 | 10.22 ± 15.915 |
| Nausea and Vomiting Score; Cycle 21 Day 1 | 12.82 ± 20.714 | 7.74 ± 12.408 |
| Nausea and Vomiting Score; Cycle 22 Day 1 | 7.02 ± 11.541 | 8.64 ± 13.374 |
| Nausea and Vomiting Score; Cycle 23 Day 1 | 5.56 ± 12.062 | 6.25 ± 11.849 |
| Nausea and Vomiting Score; Cycle 24 Day 1 | 6.67 ± 13.801 | 7.89 ± 17.004 |
| Nausea and Vomiting Score; Cycle 25 Day 1 | 13.89 ± 21.122 | 2.08 ± 8.333 |
| Nausea and Vomiting Score; Cycle 26 Day 1 | 4.17 ± 7.715 | 14.10 ± 24.387 |
| Nausea and Vomiting Score; Cycle 27 Day 1 | 5.56 ± 13.608 | 16.67 ± 28.868 |
| Nausea and Vomiting Score; Cycle 28 Day 1 | 12.50 ± 15.957 | 8.33 ± 20.412 |
| Nausea and Vomiting Score; Cycle 29 Day 1 | 16.67 ± 13.608 | 0 ± 0 |
| Nausea and Vomiting Score; Cycle 30 Day 1 | 8.33 ± 16.667 | 0 |
| Nausea and Vomiting Score; Cycle 31 Day 1 | 16.67 | — |
| Nausea and Vomiting Score; Off-treatment Visit | 13.33 ± 22.564 | 6.76 ± 13.207 |
| Pain Score; Baseline | 23.39 ± 25.410 | 23.77 ± 26.323 |
| Pain Score; Cycle 2 Day 1 | 26.79 ± 25.850 | 27.04 ± 23.862 |
| Pain Score; Cycle 3 Day 1 | 27.63 ± 24.103 | 25 ± 24.046 |
| Pain Score; Cycle 4 Day 1 | 26.67 ± 24.788 | 22.87 ± 21.486 |
| Pain Score; Cycle 5 Day 1 | 29.04 ± 26.805 | 22.97 ± 22.314 |
| Pain Score; Cycle 6 Day 1 | 26.29 ± 24.887 | 22.50 ± 25.716 |
| Pain Score; Cycle 7 Day 1 | 28.04 ± 23.189 | 23.65 ± 22.142 |
| Pain Score; Cycle 8 Day 1 | 27.38 ± 23.722 | 23.20 ± 24.949 |
| Pain Score; Cycle 9 Day 1 | 27.11 ± 23.393 | 21.01 ± 20.053 |
| Pain Score; Cycle 10 Day 1 | 26.95 ± 22.603 | 19.33 ± 18.792 |
| Pain Score; Cycle 11 Day 1 | 27.29 ± 22.319 | 18.06 ± 20.508 |
| Pain Score; Cycle 12 Day 1 | 26.41 ± 21.018 | 18.55 ± 19.814 |
| Pain Score; Cycle 13 Day 1 | 24.40 ± 20.092 | 18.48 ± 20.203 |
| Pain Score; Cycle 14 Day 1 | 22.11 ± 22.666 | 16.04 ± 19.601 |
| Pain Score; Cycle 15 Day 1 | 24.24 ± 23.966 | 17.65 ± 18.078 |
| Pain Score; Cycle 16 Day 1 | 29.67 ± 25.417 | 18.44 ± 20.628 |
| Pain Score; Cycle 17 Day 1 | 27.78 ± 25.198 | 17.50 ± 19.954 |
| Pain Score; Cycle 18 Day 1 | 25.27 ± 20.125 | 16.67 ± 18.803 |
| Pain Score; Cycle 19 Day 1 | 31.48 ± 23.266 | 19.61 ± 22.274 |
| Pain Score; Cycle 20 Day 1 | 29.63 ± 23.266 | 19.35 ± 21.558 |
| Pain Score; Cycle 21 Day 1 | 26.92 ± 23.131 | 17.86 ± 21.721 |
| Pain Score; Cycle 22 Day 1 | 23.68 ± 17.843 | 22.84 ± 24.085 |
| Pain Score; Cycle 23 Day 1 | 21.11 ± 14.729 | 18.06 ± 23.527 |
| Pain Score; Cycle 24 Day 1 | 22.22 ± 20.574 | 14.91 ± 19.160 |
| Pain Score; Cycle 25 Day 1 | 27.78 ± 23.925 | 15.63 ± 19.691 |
| Pain Score; Cycle 26 Day 1 | 27.08 ± 21.708 | 21.79 ± 27.542 |
| Pain Score; Cycle 27 Day 1 | 25 ± 20.412 | 11.90 ± 24.934 |
| Pain Score; Cycle 28 Day 1 | 25 ± 21.517 | 2.78 ± 6.804 |
| Pain Score; Cycle 29 Day 1 | 25 ± 21.517 | 6.67 ± 14.907 |
| Pain Score; Cycle 30 Day 1 | 25 ± 16.667 | 0 |
| Pain Score; Cycle 31 Day 1 | 33.33 | — |
| Pain Score; Off-treatment Visit | 28.33 ± 27.354 | 27.70 ± 28.171 |
| Dyspnea Score; Baseline | 21.18 ± 25.562 | 22.22 ± 26.006 |
| Dyspnea Score; Cycle 2 Day 1 | 18.90 ± 24.248 | 19.56 ± 23.865 |
| Dyspnea Score; Cycle 3 Day 1 | 20.63 ± 24.155 | 19.72 ± 23.871 |
| Dyspnea Score; Cycle 4 Day 1 | 19.90 ± 24.224 | 17.52 ± 20.643 |
| Dyspnea Score; Cycle 5 Day 1 | 19.16 ± 23.201 | 15.75 ± 20.925 |
| Dyspnea Score; Cycle 6 Day 1 | 16.67 ± 21.104 | 18.89 ± 23.957 |
| Dyspnea Score; Cycle 7 Day 1 | 19.37 ± 23.922 | 15.87 ± 21.728 |
| Dyspnea Score; Cycle 8 Day 1 | 19.24 ± 23.489 | 14.09 ± 20.319 |
| Dyspnea Score; Cycle 9 Day 1 | 15.93 ± 20.740 | 14.49 ± 21.712 |
| Dyspnea Score; Cycle 10 Day 1 | 17.92 ± 21.832 | 11.56 ± 19.369 |
| Dyspnea Score; Cycle 11 Day 1 | 18.63 ± 23.310 | 15.02 ± 23.764 |
| Dyspnea Score; Cycle 12 Day 1 | 13.54 ± 21.998 | 12.90 ± 22.057 |
| Dyspnea Score; Cycle 13 Day 1 | 13.69 ± 20.867 | 10.91 ± 20.341 |
| Dyspnea Score; Cycle 14 Day 1 | 15.65 ± 21.626 | 10.69 ± 20.437 |
| Dyspnea Score; Cycle 15 Day 1 | 15.15 ± 19.628 | 12.42 ± 21.040 |
| Dyspnea Score; Cycle 16 Day 1 | 16.26 ± 22.512 | 9.93 ± 16.904 |
| Dyspnea Score; Cycle 17 Day 1 | 15.74 ± 20.293 | 10 ± 20.255 |
| Dyspnea Score; Cycle 18 Day 1 | 16.13 ± 20.854 | 10.78 ± 17.829 |
| Dyspnea Score; Cycle 19 Day 1 | 15.38 ± 21.563 | 9.80 ± 17.465 |
| Dyspnea Score; Cycle 20 Day 1 | 23.46 ± 20.286 | 11.83 ± 16.212 |
| Dyspnea Score; Cycle 21 Day 1 | 15.38 ± 16.946 | 7.14 ± 13.929 |
| Dyspnea Score; Cycle 22 Day 1 | 17.54 ± 20.393 | 12.35 ± 18.829 |
| Dyspnea Score; Cycle 23 Day 1 | 13.33 ± 21.082 | 11.11 ± 18.822 |
| Dyspnea Score; Cycle 24 Day 1 | 20 ± 21.082 | 12.28 ± 16.520 |
| Dyspnea Score; Cycle 25 Day 1 | 22.22 ± 29.588 | 8.33 ± 14.907 |
| Dyspnea Score; Cycle 26 Day 1 | 16.67 ± 17.817 | 15.38 ± 22.008 |
| Dyspnea Score; Cycle 27 Day 1 | 11.11 ± 17.213 | 14.29 ± 17.817 |
| Dyspnea Score; Cycle 28 Day 1 | 16.67 ± 19.245 | 16.67 ± 18.257 |
| Dyspnea Score; Cycle 29 Day 1 | 25 ± 16.667 | 20 ± 18.257 |
| Dyspnea Score; Cycle 30 Day 1 | 16.67 ± 19.245 | 0 |
| Dyspnea Score; Cycle 31 Day 1 | 33.33 | — |
| Dyspnea Score; Off-treatment Visit | 24.68 ± 27.254 | 21.62 ± 28.898 |
| Insomnia Score; Baseline | 23.08 ± 26.972 | 22.84 ± 27.671 |
| Insomnia Score; Cycle 2 Day 1 | 26.11 ± 27.038 | 19.91 ± 25.386 |
| Insomnia Score; Cycle 3 Day 1 | 30.39 ± 29.435 | 23 ± 25.477 |
| Insomnia Score; Cycle 4 Day 1 | 26.57 ± 28.057 | 20.19 ± 24.036 |
| Insomnia Score; Cycle 5 Day 1 | 23.02 ± 26.487 | 22.05 ± 24.205 |
| Insomnia Score; Cycle 6 Day 1 | 24.86 ± 26.955 | 17.50 ± 22.019 |
| Insomnia Score; Cycle 7 Day 1 | 25.08 ± 27.651 | 20 ± 25.149 |
| Insomnia Score; Cycle 8 Day 1 | 26.46 ± 28.843 | 19.59 ± 25.346 |
| Insomnia Score; Cycle 9 Day 1 | 25.56 ± 27.392 | 16.67 ± 21.255 |
| Insomnia Score; Cycle 10 Day 1 | 24.58 ± 25.844 | 18.22 ± 22.789 |
| Insomnia Score; Cycle 11 Day 1 | 24.02 ± 26.918 | 17.37 ± 24.468 |
| Insomnia Score; Cycle 12 Day 1 | 23.44 ± 23.518 | 13.98 ± 22.216 |
| Insomnia Score; Cycle 13 Day 1 | 21.43 ± 21.489 | 13.33 ± 21.849 |
| Insomnia Score; Cycle 14 Day 1 | 18.06 ± 23.778 | 11.95 ± 21.774 |
| Insomnia Score; Cycle 15 Day 1 | 18.94 ± 20.832 | 16 ± 23.561 |
| Insomnia Score; Cycle 16 Day 1 | 20.33 ± 20.921 | 14.89 ± 21.768 |
| Insomnia Score; Cycle 17 Day 1 | 17.59 ± 16.877 | 13.33 ± 21.082 |
| Insomnia Score; Cycle 18 Day 1 | 27.96 ± 25.958 | 11.76 ± 19.903 |
| Insomnia Score; Cycle 19 Day 1 | 24.69 ± 25.474 | 13.73 ± 21.893 |
| Insomnia Score; Cycle 20 Day 1 | 25.93 ± 25.036 | 12.90 ± 20.507 |
| Insomnia Score; Cycle 21 Day 1 | 23.08 ± 27.919 | 10.71 ± 18.265 |
| Insomnia Score; Cycle 22 Day 1 | 21.05 ± 19.909 | 6.17 ± 16.111 |
| Insomnia Score; Cycle 23 Day 1 | 26.67 ± 22.537 | 11.11 ± 23.399 |
| Insomnia Score; Cycle 24 Day 1 | 24.44 ± 26.627 | 12.28 ± 19.909 |
| Insomnia Score; Cycle 25 Day 1 | 16.67 ± 17.408 | 12.50 ± 20.638 |
| Insomnia Score; Cycle 26 Day 1 | 16.67 ± 17.817 | 20.51 ± 32.026 |
| Insomnia Score; Cycle 27 Day 1 | 22.22 ± 17.213 | 9.52 ± 16.265 |
| Insomnia Score; Cycle 28 Day 1 | 25 ± 16.667 | 11.11 ± 17.213 |
| Insomnia Score; Cycle 29 Day 1 | 25 ± 16.667 | 13.33 ± 18.257 |
| Insomnia Score; Cycle 30 Day 1 | 25 ± 16.667 | 0 |
| Insomnia Score; Cycle 31 Day 1 | 33.33 | — |
| Insomnia Score; Off-treatment Visit | 32.05 ± 32.430 | 28.83 ± 31.850 |
| Appetite Loss Score; Baseline | 15.79 ± 24.606 | 18.31 ± 27.060 |
| Appetite Loss Score; Cycle 2 Day 1 | 26.79 ± 31.129 | 27.56 ± 32.020 |
| Appetite Loss Score; Cycle 3 Day 1 | 31.97 ± 31.905 | 29.81 ± 31.687 |
| Appetite Loss Score; Cycle 4 Day 1 | 32.09 ± 31.239 | 30.90 ± 32.749 |
| Appetite Loss Score; Cycle 5 Day 1 | 30.47 ± 29.881 | 30.67 ± 32.129 |
| Appetite Loss Score; Cycle 6 Day 1 | 30.35 ± 31.365 | 26.11 ± 29.996 |
| Appetite Loss Score; Cycle 7 Day 1 | 29.28 ± 31.956 | 26.98 ± 28.154 |
| Appetite Loss Score; Cycle 8 Day 1 | 29.25 ± 31.483 | 25.00 ± 26.491 |
| Appetite Loss Score; Cycle 9 Day 1 | 29.30 ± 30.565 | 25.36 ± 27.678 |
| Appetite Loss Score; Cycle 10 Day 1 | 27.57 ± 29.716 | 22.22 ± 22.815 |
| Appetite Loss Score; Cycle 11 Day 1 | 24.15 ± 27.938 | 22.07 ± 26.988 |
| Appetite Loss Score; Cycle 12 Day 1 | 22.05 ± 24.493 | 18.82 ± 25.336 |
| Appetite Loss Score; Cycle 13 Day 1 | 23.21 ± 25.362 | 17.28 ± 21.221 |
| Appetite Loss Score; Cycle 14 Day 1 | 19.73 ± 24.456 | 17.61 ± 24.111 |
| Appetite Loss Score; Cycle 15 Day 1 | 17.42 ± 23.282 | 24.18 ± 30.608 |
| Appetite Loss Score; Cycle 16 Day 1 | 23.58 ± 27.125 | 22.70 ± 27.014 |
| Appetite Loss Score; Cycle 17 Day 1 | 20.37 ± 21.496 | 22.50 ± 25.473 |
| Appetite Loss Score; Cycle 18 Day 1 | 19.35 ± 22.401 | 22.22 ± 24.533 |
| Appetite Loss Score; Cycle 19 Day 1 | 19.75 ± 23.130 | 20.59 ± 25.969 |
| Appetite Loss Score; Cycle 20 Day 1 | 23.46 ± 25.844 | 21.51 ± 30.488 |
| Appetite Loss Score; Cycle 21 Day 1 | 23.08 ± 20.590 | 15.48 ± 21.242 |
| Appetite Loss Score; Cycle 22 Day 1 | 17.54 ± 20.393 | 17.28 ± 25.099 |
| Appetite Loss Score; Cycle 23 Day 1 | 17.78 ± 24.774 | 20.83 ± 27.474 |
| Appetite Loss Score; Cycle 24 Day 1 | 13.33 ± 24.560 | 15.79 ± 25.744 |
| Appetite Loss Score; Cycle 25 Day 1 | 19.44 ± 22.285 | 18.75 ± 29.736 |
| Appetite Loss Score; Cycle 26 Day 1 | 29.17 ± 27.817 | 23.08 ± 34.385 |
| Appetite Loss Score; Cycle 27 Day 1 | 16.67 ± 18.257 | 9.52 ± 16.265 |
| Appetite Loss Score; Cycle 28 Day 1 | 8.33 ± 16.667 | 11.11 ± 17.213 |
| Appetite Loss Score; Cycle 29 Day 1 | 16.67 ± 19.245 | 0 ± 0 |
| Appetite Loss Score; Cycle 30 Day 1 | 8.33 ± 16.667 | 0 |
| Appetite Loss Score; Cycle 31 Day 1 | 0 | — |
| Appetite Loss Score; Off-treatment Visit | 29.58 ± 31.820 | 25.23 ± 32.082 |
| Constipation Score; Baseline | 15.98 ± 24.876 | 12.55 ± 23.501 |
| Constipation Score; Cycle 2 Day 1 | 10.40 ± 20.274 | 11.11 ± 21.035 |
| Constipation Score; Cycle 3 Day 1 | 9.52 ± 20.644 | 10.80 ± 20.456 |
| Constipation Score; Cycle 4 Day 1 | 11.11 ± 21.930 | 9.80 ± 19.081 |
| Constipation Score; Cycle 5 Day 1 | 12.24 ± 20.438 | 9.87 ± 19.411 |
| Constipation Score; Cycle 6 Day 1 | 8.47 ± 16.905 | 8.47 ± 19.090 |
| Constipation Score; Cycle 7 Day 1 | 11.01 ± 22.874 | 7.44 ± 16.785 |
| Constipation Score; Cycle 8 Day 1 | 9.62 ± 18.608 | 7.22 ± 14.614 |
| Constipation Score; Cycle 9 Day 1 | 6.23 ± 15.644 | 9.42 ± 19.967 |
| Constipation Score; Cycle 10 Day 1 | 6.58 ± 13.354 | 8.00 ± 18.042 |
| Constipation Score; Cycle 11 Day 1 | 6.76 ± 15.739 | 7.98 ± 18.227 |
| Constipation Score; Cycle 12 Day 1 | 5.64 ± 13.906 | 9.68 ± 18.492 |
| Constipation Score; Cycle 13 Day 1 | 3.64 ± 12.294 | 9.09 ± 18.653 |
| Constipation Score; Cycle 14 Day 1 | 5.44 ± 14.186 | 7.69 ± 16.978 |
| Constipation Score; Cycle 15 Day 1 | 5.43 ± 17.714 | 9.33 ± 19.095 |
| Constipation Score; Cycle 16 Day 1 | 5.98 ± 16.879 | 9.93 ± 18.277 |
| Constipation Score; Cycle 17 Day 1 | 11.11 ± 22.537 | 5.00 ± 12.054 |
| Constipation Score; Cycle 18 Day 1 | 7.53 ± 14.167 | 7.84 ± 16.532 |
| Constipation Score; Cycle 19 Day 1 | 9.88 ± 18.057 | 9.80 ± 20.969 |
| Constipation Score; Cycle 20 Day 1 | 8.64 ± 17.523 | 8.60 ± 22.718 |
| Constipation Score; Cycle 21 Day 1 | 8.97 ± 17.783 | 7.14 ± 16.623 |
| Constipation Score; Cycle 22 Day 1 | 7.02 ± 13.962 | 7.41 ± 19.245 |
| Constipation Score; Cycle 23 Day 1 | 6.67 ± 13.801 | 11.11 ± 21.234 |
| Constipation Score; Cycle 24 Day 1 | 4.44 ± 17.213 | 8.77 ± 21.779 |
| Constipation Score; Cycle 25 Day 1 | 5.56 ± 12.975 | 18.75 ± 29.736 |
| Constipation Score; Cycle 26 Day 1 | 8.33 ± 15.430 | 15.38 ± 25.875 |
| Constipation Score; Cycle 27 Day 1 | 16.67 ± 27.889 | 0 ± 0 |
| Constipation Score; Cycle 28 Day 1 | 25.00 ± 31.914 | 0 ± 0 |
| Constipation Score; Cycle 29 Day 1 | 25.00 ± 31.914 | 0 ± 0 |
| Constipation Score; Cycle 30 Day 1 | 16.67 ± 33.333 | 0 |
| Constipation Score; Cycle 31 Day 1 | 33.33 | — |
| Constipation Score; Off-treatment Visit | 13.33 ± 23.481 | 12.61 ± 21.863 |
| Diarrhea Score; Baseline | 6.43 ± 15.045 | 6.79 ± 15.823 |
| Diarrhea Score; Cycle 2 Day 1 | 22.29 ± 29.572 | 17.66 ± 26.333 |
| Diarrhea Score; Cycle 3 Day 1 | 32.21 ± 30.858 | 27.19 ± 32.023 |
| Diarrhea Score; Cycle 4 Day 1 | 35.59 ± 33.634 | 29.41 ± 28.991 |
| Diarrhea Score; Cycle 5 Day 1 | 28.61 ± 28.085 | 29.33 ± 29.207 |
| Diarrhea Score; Cycle 6 Day 1 | 31.96 ± 30.550 | 26.89 ± 27.541 |
| Diarrhea Score; Cycle 7 Day 1 | 33.64 ± 31.885 | 31.75 ± 27.881 |
| Diarrhea Score; Cycle 8 Day 1 | 29.55 ± 28.818 | 31.27 ± 28.793 |
| Diarrhea Score; Cycle 9 Day 1 | 34.43 ± 33.129 | 28.62 ± 28.637 |
| Diarrhea Score; Cycle 10 Day 1 | 29.22 ± 29.992 | 29.33 ± 25.088 |
| Diarrhea Score; Cycle 11 Day 1 | 28.02 ± 28.367 | 26.85 ± 26.619 |
| Diarrhea Score; Cycle 12 Day 1 | 28.49 ± 31.273 | 22.78 ± 23.363 |
| Diarrhea Score; Cycle 13 Day 1 | 26.19 ± 28.223 | 23.03 ± 25.558 |
| Diarrhea Score; Cycle 14 Day 1 | 26.53 ± 25.440 | 24.36 ± 22.008 |
| Diarrhea Score; Cycle 15 Day 1 | 29.55 ± 29.828 | 30.07 ± 26.038 |
| Diarrhea Score; Cycle 16 Day 1 | 20.33 ± 27.767 | 23.40 ± 21.886 |
| Diarrhea Score; Cycle 17 Day 1 | 21.30 ± 24.107 | 29.17 ± 28.432 |
| Diarrhea Score; Cycle 18 Day 1 | 21.51 ± 25.164 | 25.49 ± 23.296 |
| Diarrhea Score; Cycle 19 Day 1 | 23.46 ± 28.963 | 21.57 ± 21.528 |
| Diarrhea Score; Cycle 20 Day 1 | 19.75 ± 23.130 | 22.58 ± 23.392 |
| Diarrhea Score; Cycle 21 Day 1 | 20.51 ± 26.795 | 21.43 ± 18.624 |
| Diarrhea Score; Cycle 22 Day 1 | 17.54 ± 20.393 | 24.69 ± 19.812 |
| Diarrhea Score; Cycle 23 Day 1 | 15.56 ± 17.213 | 22.22 ± 16.051 |
| Diarrhea Score; Cycle 24 Day 1 | 11.11 ± 16.265 | 19.30 ± 16.909 |
| Diarrhea Score; Cycle 25 Day 1 | 19.44 ± 22.285 | 18.75 ± 17.078 |
| Diarrhea Score; Cycle 26 Day 1 | 25.00 ± 29.547 | 17.95 ± 17.296 |
| Diarrhea Score; Cycle 27 Day 1 | 33.33 ± 21.082 | 33.33 ± 19.245 |
| Diarrhea Score; Cycle 28 Day 1 | 16.67 ± 19.245 | 22.22 ± 17.213 |
| Diarrhea Score; Cycle 29 Day 1 | 8.33 ± 16.667 | 20.00 ± 18.257 |
| Diarrhea Score; Cycle 30 Day 1 | 16.67 ± 19.245 | 0 |
| Diarrhea Score; Cycle 31 Day 1 | 33.33 | — |
| Diarrhea Score; Off-treatment Visit | 18.33 ± 25.380 | 12.16 ± 19.565 |
| Financial Difficulties Score; Baseline | 21.76 ± 28.382 | 20.37 ± 29.076 |
| Financial Difficulties Score; Cycle 2 Day 1 | 21.08 ± 28.177 | 15.01 ± 24.852 |
| Financial Difficulties Score; Cycle 3 Day 1 | 23.13 ± 27.201 | 18.20 ± 27.451 |
| Financial Difficulties Score; Cycle 4 Day 1 | 22.90 ± 27.761 | 16.42 ± 25.113 |
| Financial Difficulties Score; Cycle 5 Day 1 | 22.93 ± 28.213 | 18.78 ± 29.058 |
| Financial Difficulties Score; Cycle 6 Day 1 | 25.00 ± 27.416 | 17.80 ± 25.666 |
| Financial Difficulties Score; Cycle 7 Day 1 | 30.16 ± 31.866 | 15.87 ± 24.062 |
| Financial Difficulties Score; Cycle 8 Day 1 | 25.43 ± 29.176 | 17.53 ± 24.576 |
| Financial Difficulties Score; Cycle 9 Day 1 | 25.56 ± 30.002 | 16.67 ± 23.440 |
| Financial Difficulties Score; Cycle 10 Day 1 | 22.50 ± 27.952 | 17.35 ± 24.913 |
| Financial Difficulties Score; Cycle 11 Day 1 | 26.26 ± 30.108 | 16.20 ± 24.382 |
| Financial Difficulties Score; Cycle 12 Day 1 | 24.87 ± 28.061 | 16.11 ± 24.156 |
| Financial Difficulties Score; Cycle 13 Day 1 | 23.03 ± 26.351 | 19.14 ± 25.577 |
| Financial Difficulties Score; Cycle 14 Day 1 | 20.83 ± 22.413 | 17.31 ± 25.127 |
| Financial Difficulties Score; Cycle 15 Day 1 | 21.71 ± 27.103 | 19.61 ± 26.813 |
| Financial Difficulties Score; Cycle 16 Day 1 | 21.67 ± 25.654 | 17.02 ± 24.937 |
| Financial Difficulties Score; Cycle 17 Day 1 | 23.81 ± 27.501 | 19.17 ± 27.099 |
| Financial Difficulties Score; Cycle 18 Day 1 | 17.20 ± 18.995 | 19.61 ± 28.566 |
| Financial Difficulties Score; Cycle 19 Day 1 | 18.52 ± 19.245 | 20.59 ± 28.444 |
| Financial Difficulties Score; Cycle 20 Day 1 | 16.05 ± 21.424 | 20.43 ± 30.644 |
| Financial Difficulties Score; Cycle 21 Day 1 | 19.23 ± 21.444 | 20.24 ± 27.725 |
| Financial Difficulties Score; Cycle 22 Day 1 | 24.56 ± 24.450 | 20.99 ± 29.451 |
| Financial Difficulties Score; Cycle 23 Day 1 | 17.78 ± 17.213 | 23.61 ± 31.819 |
| Financial Difficulties Score; Cycle 24 Day 1 | 17.78 ± 21.331 | 19.30 ± 25.618 |
| Financial Difficulties Score; Cycle 25 Day 1 | 16.67 ± 22.473 | 16.67 ± 24.343 |
| Financial Difficulties Score; Cycle 26 Day 1 | 20.83 ± 24.801 | 20.51 ± 32.026 |
| Financial Difficulties Score; Cycle 27 Day 1 | 16.67 ± 18.257 | 0 ± 0 |
| Financial Difficulties Score; Cycle 28 Day 1 | 25.00 ± 16.667 | 0 ± 0 |
| Financial Difficulties Score; Cycle 29 Day 1 | 25.00 ± 16.667 | 0 ± 0 |
| Financial Difficulties Score; Cycle 30 Day 1 | 25.00 ± 16.667 | 0 |
| Financial Difficulties Score; Cycle 31 Day 1 | 0 | — |
| Financial Difficulties Score; Off-treatment Visit | 31.65 ± 32.423 | 25.11 ± 30.318 |
The EQ-5D-3L is a health profile questionnaire assessing quality of life along 5 dimensions. Participants rate 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 5-15 with "5" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. The EQ-5D index was calculated by applying preference-based weights (tariffs) to the scores of the five health state dimensions. Index values can range from -1 to 1, with 0 representing a health state equivalent to death and 1 representing perfect health. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best).
| score on a scale | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| EQ-5D Index Score; Baseline | 0.76 ± 0.216 | 0.78 ± 0.232 |
| EQ-5D Index Score; Cycle 2 Day 1 | 0.76 ± 0.178 | 0.76 ± 0.230 |
| EQ-5D Index Score; Cycle 3 Day 1 | 0.73 ± 0.232 | 0.78 ± 0.239 |
| EQ-5D Index Score; Cycle 4 Day 1 | 0.73 ± 0.213 | 0.78 ± 0.236 |
| EQ-5D Index Score; Cycle 5 Day 1 | 0.73 ± 0.212 | 0.78 ± 0.199 |
| EQ-5D Index Score; Cycle 6 Day 1 | 0.73 ± 0.220 | 0.77 ± 0.225 |
| EQ-5D Index Score; Cycle 7 Day 1 | 0.71 ± 0.219 | 0.78 ± 0.196 |
| EQ-5D Index Score; Cycle 8 Day 1 | 0.75 ± 0.187 | 0.80 ± 0.187 |
| EQ-5D Index Score; Cycle 9 Day 1 | 0.73 ± 0.192 | 0.79 ± 0.192 |
| EQ-5D Index Score; Cycle 10 Day 1 | 0.76 ± 0.186 | 0.81 ± 0.177 |
| EQ-5D Index Score; Cycle 11 Day 1 | 0.77 ± 0.185 | 0.82 ± 0.82 |
| EQ-5D Index Score; Cycle 12 Day 1 | 0.77 ± 0.173 | 0.83 ± 0.161 |
| EQ-5D Index Score; Cycle 13 Day 1 | 0.76 ± 0.157 | 0.82 ± 0.179 |
| EQ-5D Index Score; Cycle 14 Day 1 | 0.77 ± 0.186 | 0.83 ± 0.163 |
| EQ-5D Index Score; Cycle 15 Day 1 | 0.76 ± 0.191 | 0.81 ± 0.165 |
| EQ-5D Index Score; Cycle 16 Day 1 | 0.73 ± 0.179 | 0.81 ± 0.212 |
| EQ-5D Index Score; Cycle 17 Day 1 | 0.73 ± 0.211 | 0.83 ± 0.158 |
| EQ-5D Index Score; Cycle 18 Day 1 | 0.76 ± 0.148 | 0.84 ± 0.177 |
| EQ-5D Index Score; Cycle 19 Day 1 | 0.69 ± 0.266 | 0.79 ± 0.205 |
| EQ-5D Index Score; Cycle 20 Day 1 | 0.70 ± 0.259 | 0.82 ± 0.167 |
| EQ-5D Index Score; Cycle 21 Day 1 | 0.73 ± 0.223 | 0.83 ± 0.180 |
| EQ-5D Index Score; Cycle 22 Day 1 | 0.74 ± 0.157 | 0.85 ± 0.173 |
| EQ-5D Index Score; Cycle 23 Day 1 | 0.74 ± 0.149 | 0.82 ± 0.242 |
| EQ-5D Index Score; Cycle 24 Day 1 | 0.75 ± 0.172 | 0.84 ± 0.156 |
| EQ-5D Index Score; Cycle 25 Day 1 | 0.70 ± 0.245 | 0.83 ± 0.175 |
| EQ-5D Index Score; Cycle 26 Day 1 | 0.72 ± 0.170 | 0.73 ± 0.438 |
| EQ-5D Index Score; Cycle 27 Day 1 | 0.77 ± 0.135 | 0.93 ± 0.117 |
| EQ-5D Index Score; Cycle 28 Day 1 | 0.73 ± 0.112 | 0.97 ± 0.067 |
| EQ-5D Index Score; Cycle 29 Day 1 | 0.74 ± 0.120 | 0.96 ± 0.075 |
| EQ-5D Index Score; Cycle 30 Day 1 | 0.61 ± 0.391 | 1 |
| EQ-5D Index Score; Cycle 31 Day 1 | 0.87 | — |
| EQ-5D Index Score; Off-treatment Visit | 0.61 ± 0.331 | 0.68 ± 0.314 |
| EQ-VAS Score; Baseline | 68.57 ± 18.348 | 70.01 ± 20.552 |
| EQ-VAS Score; Cycle 2 Day 1 | 66.05 ± 18.531 | 69.52 ± 19.155 |
| EQ-VAS Score; Cycle 3 Day 1 | 66.22 ± 17.804 | 70.71 ± 17.648 |
| EQ-VAS Score; Cycle 4 Day 1 | 65.69 ± 18.265 | 69.66 ± 17.784 |
| EQ-VAS Score; Cycle 5 Day 1 | 65.86 ± 18.908 | 70.30 ± 19.492 |
| EQ-VAS Score; Cycle 6 Day 1 | 65.53 ± 20.027 | 71.73 ± 17.366 |
| EQ-VAS Score; Cycle 7 Day 1 | 65.74 ± 18.063 | 70.39 ± 19.387 |
| EQ-VAS Score; Cycle 8 Day 1 | 64.16 ± 18.969 | 70.40 ± 20.130 |
| EQ-VAS Score; Cycle 9 Day 1 | 65.51 ± 17.670 | 69.92 ± 19.452 |
| EQ-VAS Score; Cycle 10 Day 1 | 66.92 ± 17.747 | 73.18 ± 20.167 |
| EQ-VAS Score; Cycle 11 Day 1 | 67.74 ± 16.850 | 73.21 ± 19.310 |
| EQ-VAS Score; Cycle 12 Day 1 | 66.46 ± 18.680 | 74.46 ± 17.139 |
| EQ-VAS Score; Cycle 13 Day 1 | 65.64 ± 19.690 | 74.35 ± 17.766 |
| EQ-VAS Score; Cycle 14 Day 1 | 66.41 ± 17.839 | 74.40 ± 17.678 |
| EQ-VAS Score; Cycle 15 Day 1 | 67.05 ± 17.847 | 72.58 ± 19.060 |
| EQ-VAS Score; Cycle 16 Day 1 | 66.54 ± 18.118 | 72.80 ± 17.733 |
| EQ-VAS Score; Cycle 17 Day 1 | 65.78 ± 17.755 | 73.80 ± 17.593 |
| EQ-VAS Score; Cycle 18 Day 1 | 64.70 ± 18.170 | 73.71 ± 16.665 |
| EQ-VAS Score; Cycle 19 Day 1 | 62.15 ± 20.676 | 71.76 ± 19.272 |
| EQ-VAS Score; Cycle 20 Day 1 | 62.70 ± 19.779 | 72.07 ± 19.293 |
| EQ-VAS Score; Cycle 21 Day 1 | 62.12 ± 17.974 | 76.46 ± 16.836 |
| EQ-VAS Score; Cycle 22 Day 1 | 65.21 ± 14.722 | 74.44 ± 16.860 |
| EQ-VAS Score; Cycle 23 Day 1 | 67.73 ± 15.650 | 73.67 ± 17.704 |
| EQ-VAS Score; Cycle 24 Day 1 | 65.27 ± 19.381 | 71.21 ± 21.212 |
| EQ-VAS Score; Cycle 25 Day 1 | 60.58 ± 19.313 | 72.81 ± 16.897 |
| EQ-VAS Score; Cycle 26 Day 1 | 64.13 ± 16.313 | 65.23 ± 25.652 |
| EQ-VAS Score; Cycle 27 Day 1 | 61.83 ± 18.357 | 77.43 ± 16.762 |
| EQ-VAS Score; Cycle 28 Day 1 | 54.25 ± 8.694 | 77.50 ± 20.907 |
| EQ-VAS Score; Cycle 29 Day 1 | 52.75 ± 12.093 | 74 ± 21.036 |
| EQ-VAS Score; Cycle 30 Day 1 | 51.75 ± 11.295 | 50 |
| EQ-VAS Score; Cycle 31 Day 1 | 35 | — |
| EQ-VAS Score; Off-treatment Visit | 58.48 ± 23.516 | 62.66 ± 22.252 |
PFS2, defined as the time from randomization to the date of PD after next line of therapy or death from any cause, whichever occurred first based on investigator assessment according to RECIST v1.1. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Median PFS2 was analyzed using the Kaplan-Meier product-limit estimates for each treatment group and presented with 2-sided 95% CI. As pre-specified in protocol, data for this secondary outcome measure was collected and analyzed till the primary analysis only.
| months | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| Progression-free Survival After Next Line of Therapy (PFS2) | 18.2 (13.1 to 22.5) | 19.5 (14.1 to 23.8) |
Collected over From date of first dose of study drug up to 28 days after last dose of study drug (up to 71 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenvatinib 14 mg + Everolimus 5 mg | 71/173 (41%) | 92/173 (53.2%) | 172/173 (99.4%) |
| Lenvatinib 18 mg + Everolimus 5 mg | 60/168 (35.7%) | 87/168 (51.8%) | 166/168 (98.8%) |
| Event | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| PneumoniaInfections and infestations | 13/173 | 7/168 |
| DiarrhoeaGastrointestinal disorders | 11/173 | 6/168 |
| Acute kidney injuryRenal and urinary disorders | 3/173 | 6/168 |
| VomitingGastrointestinal disorders | 6/173 | 2/168 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/173 | 5/168 |
| Blood creatinine increasedInvestigations | 2/173 | 4/168 |
| PyrexiaGeneral disorders | 4/173 | 1/168 |
| GastroenteritisInfections and infestations | 4/173 | 1/168 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/173 | 3/168 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/173 | 3/168 |
| Event | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 117/173 | 123/168 |
| ProteinuriaRenal and urinary disorders | 40/173 | 66/168 |
| Decreased appetiteMetabolism and nutrition disorders | 64/173 | 57/168 |
| StomatitisGastrointestinal disorders | 61/173 | 49/168 |
| HypertensionVascular disorders | 54/173 | 59/168 |
| NauseaGastrointestinal disorders | 54/173 | 52/168 |
| FatigueGeneral disorders | 51/173 | 50/168 |
| VomitingGastrointestinal disorders | 41/173 | 43/168 |
| Weight decreasedInvestigations | 36/173 | 41/168 |
| AstheniaGeneral disorders | 42/173 | 39/168 |
Full analysis set (FAS) included all randomized participants.
| Age, Continuous(years) | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg | Total |
|---|---|---|---|
| Mean | 60.5 ± 9.59 | 61.5 ± 9.90 | 61.0 ± 9.74 |
| Sex: Female, Male(Participants) | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg | Total |
|---|---|---|---|
| Female | 39 | 42 | 81 |
| Male | 133 | 129 | 262 |
| Ethnicity (NIH/OMB)(Participants) | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 8 | 12 |
| Not Hispanic or Latino | 168 | 163 | 331 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Lenvatinib 14 mg + Everolimus 5 mg | Lenvatinib 18 mg + Everolimus 5 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 33 | 27 | 60 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 137 | 140 | 277 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 4 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2017 to primary completion in Feb 2020, 29 months.
Results were first posted in Mar 2021, 1 year after primary completion.
Of 47 industry-sponsored phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 29 months is below that.
Counting every sponsor, half of 230 studies reached it within 58 months; a quarter within 33 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib